Cargando…

The added value of PSMA PET/MR radiomics for prostate cancer staging

PURPOSE: To evaluate the performance of combined PET and multiparametric MRI (mpMRI) radiomics for the group-wise prediction of postsurgical Gleason scores (psGSs) in primary prostate cancer (PCa) patients. METHODS: Patients with PCa, who underwent [(68) Ga]Ga-PSMA-11 PET/MRI followed by radical pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Solari, Esteban Lucas, Gafita, Andrei, Schachoff, Sylvia, Bogdanović, Borjana, Villagrán Asiares, Alberto, Amiel, Thomas, Hui, Wang, Rauscher, Isabel, Visvikis, Dimitris, Maurer, Tobias, Schwamborn, Kristina, Mustafa, Mona, Weber, Wolfgang, Navab, Nassir, Eiber, Matthias, Hatt, Mathieu, Nekolla, Stephan G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8803696/
https://www.ncbi.nlm.nih.gov/pubmed/34255130
http://dx.doi.org/10.1007/s00259-021-05430-z
_version_ 1784642924059820032
author Solari, Esteban Lucas
Gafita, Andrei
Schachoff, Sylvia
Bogdanović, Borjana
Villagrán Asiares, Alberto
Amiel, Thomas
Hui, Wang
Rauscher, Isabel
Visvikis, Dimitris
Maurer, Tobias
Schwamborn, Kristina
Mustafa, Mona
Weber, Wolfgang
Navab, Nassir
Eiber, Matthias
Hatt, Mathieu
Nekolla, Stephan G.
author_facet Solari, Esteban Lucas
Gafita, Andrei
Schachoff, Sylvia
Bogdanović, Borjana
Villagrán Asiares, Alberto
Amiel, Thomas
Hui, Wang
Rauscher, Isabel
Visvikis, Dimitris
Maurer, Tobias
Schwamborn, Kristina
Mustafa, Mona
Weber, Wolfgang
Navab, Nassir
Eiber, Matthias
Hatt, Mathieu
Nekolla, Stephan G.
author_sort Solari, Esteban Lucas
collection PubMed
description PURPOSE: To evaluate the performance of combined PET and multiparametric MRI (mpMRI) radiomics for the group-wise prediction of postsurgical Gleason scores (psGSs) in primary prostate cancer (PCa) patients. METHODS: Patients with PCa, who underwent [(68) Ga]Ga-PSMA-11 PET/MRI followed by radical prostatectomy, were included in this retrospective analysis (n = 101). Patients were grouped by psGS in three categories: ISUP grades 1–3, ISUP grade 4, and ISUP grade 5. mpMRI images included T1-weighted, T2-weighted, and apparent diffusion coefficient (ADC) map. Whole-prostate segmentations were performed on each modality, and image biomarker standardization initiative (IBSI)-compliant radiomic features were extracted. Nine support vector machine (SVM) models were trained: four single-modality radiomic models (PET, T1w, T2w, ADC); three PET + MRI double-modality models (PET + T1w, PET + T2w, PET + ADC), and two baseline models (one with patient data, one image-based) for comparison. A sixfold stratified cross-validation was performed, and balanced accuracies (bAcc) of the predictions of the best-performing models were reported and compared through Student’s t-tests. The predictions of the best-performing model were compared against biopsy GS (bGS). RESULTS: All radiomic models outperformed the baseline models. The best-performing (mean ± stdv [%]) single-modality model was the ADC model (76 ± 6%), although not significantly better (p > 0.05) than other single-modality models (T1w: 72 ± 3%, T2w: 73 ± 2%; PET: 75 ± 5%). The overall best-performing model combined PET + ADC radiomics (82 ± 5%). It significantly outperformed most other double-modality (PET + T1w: 74 ± 5%, p = 0.026; PET + T2w: 71 ± 4%, p = 0.003) and single-modality models (PET: p = 0.042; T1w: p = 0.002; T2w: p = 0.003), except the ADC-only model (p = 0.138). In this initial cohort, the PET + ADC model outperformed bGS overall (82.5% vs 72.4%) in the prediction of psGS. CONCLUSION: All single- and double-modality models outperformed the baseline models, showing their potential in the prediction of GS, even with an unbalanced cohort. The best-performing model included PET + ADC radiomics, suggesting a complementary value of PSMA-PET and ADC radiomics. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00259-021-05430-z.
format Online
Article
Text
id pubmed-8803696
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-88036962022-02-02 The added value of PSMA PET/MR radiomics for prostate cancer staging Solari, Esteban Lucas Gafita, Andrei Schachoff, Sylvia Bogdanović, Borjana Villagrán Asiares, Alberto Amiel, Thomas Hui, Wang Rauscher, Isabel Visvikis, Dimitris Maurer, Tobias Schwamborn, Kristina Mustafa, Mona Weber, Wolfgang Navab, Nassir Eiber, Matthias Hatt, Mathieu Nekolla, Stephan G. Eur J Nucl Med Mol Imaging Original Article PURPOSE: To evaluate the performance of combined PET and multiparametric MRI (mpMRI) radiomics for the group-wise prediction of postsurgical Gleason scores (psGSs) in primary prostate cancer (PCa) patients. METHODS: Patients with PCa, who underwent [(68) Ga]Ga-PSMA-11 PET/MRI followed by radical prostatectomy, were included in this retrospective analysis (n = 101). Patients were grouped by psGS in three categories: ISUP grades 1–3, ISUP grade 4, and ISUP grade 5. mpMRI images included T1-weighted, T2-weighted, and apparent diffusion coefficient (ADC) map. Whole-prostate segmentations were performed on each modality, and image biomarker standardization initiative (IBSI)-compliant radiomic features were extracted. Nine support vector machine (SVM) models were trained: four single-modality radiomic models (PET, T1w, T2w, ADC); three PET + MRI double-modality models (PET + T1w, PET + T2w, PET + ADC), and two baseline models (one with patient data, one image-based) for comparison. A sixfold stratified cross-validation was performed, and balanced accuracies (bAcc) of the predictions of the best-performing models were reported and compared through Student’s t-tests. The predictions of the best-performing model were compared against biopsy GS (bGS). RESULTS: All radiomic models outperformed the baseline models. The best-performing (mean ± stdv [%]) single-modality model was the ADC model (76 ± 6%), although not significantly better (p > 0.05) than other single-modality models (T1w: 72 ± 3%, T2w: 73 ± 2%; PET: 75 ± 5%). The overall best-performing model combined PET + ADC radiomics (82 ± 5%). It significantly outperformed most other double-modality (PET + T1w: 74 ± 5%, p = 0.026; PET + T2w: 71 ± 4%, p = 0.003) and single-modality models (PET: p = 0.042; T1w: p = 0.002; T2w: p = 0.003), except the ADC-only model (p = 0.138). In this initial cohort, the PET + ADC model outperformed bGS overall (82.5% vs 72.4%) in the prediction of psGS. CONCLUSION: All single- and double-modality models outperformed the baseline models, showing their potential in the prediction of GS, even with an unbalanced cohort. The best-performing model included PET + ADC radiomics, suggesting a complementary value of PSMA-PET and ADC radiomics. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00259-021-05430-z. Springer Berlin Heidelberg 2021-07-13 2022 /pmc/articles/PMC8803696/ /pubmed/34255130 http://dx.doi.org/10.1007/s00259-021-05430-z Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Solari, Esteban Lucas
Gafita, Andrei
Schachoff, Sylvia
Bogdanović, Borjana
Villagrán Asiares, Alberto
Amiel, Thomas
Hui, Wang
Rauscher, Isabel
Visvikis, Dimitris
Maurer, Tobias
Schwamborn, Kristina
Mustafa, Mona
Weber, Wolfgang
Navab, Nassir
Eiber, Matthias
Hatt, Mathieu
Nekolla, Stephan G.
The added value of PSMA PET/MR radiomics for prostate cancer staging
title The added value of PSMA PET/MR radiomics for prostate cancer staging
title_full The added value of PSMA PET/MR radiomics for prostate cancer staging
title_fullStr The added value of PSMA PET/MR radiomics for prostate cancer staging
title_full_unstemmed The added value of PSMA PET/MR radiomics for prostate cancer staging
title_short The added value of PSMA PET/MR radiomics for prostate cancer staging
title_sort added value of psma pet/mr radiomics for prostate cancer staging
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8803696/
https://www.ncbi.nlm.nih.gov/pubmed/34255130
http://dx.doi.org/10.1007/s00259-021-05430-z
work_keys_str_mv AT solariestebanlucas theaddedvalueofpsmapetmrradiomicsforprostatecancerstaging
AT gafitaandrei theaddedvalueofpsmapetmrradiomicsforprostatecancerstaging
AT schachoffsylvia theaddedvalueofpsmapetmrradiomicsforprostatecancerstaging
AT bogdanovicborjana theaddedvalueofpsmapetmrradiomicsforprostatecancerstaging
AT villagranasiaresalberto theaddedvalueofpsmapetmrradiomicsforprostatecancerstaging
AT amielthomas theaddedvalueofpsmapetmrradiomicsforprostatecancerstaging
AT huiwang theaddedvalueofpsmapetmrradiomicsforprostatecancerstaging
AT rauscherisabel theaddedvalueofpsmapetmrradiomicsforprostatecancerstaging
AT visvikisdimitris theaddedvalueofpsmapetmrradiomicsforprostatecancerstaging
AT maurertobias theaddedvalueofpsmapetmrradiomicsforprostatecancerstaging
AT schwambornkristina theaddedvalueofpsmapetmrradiomicsforprostatecancerstaging
AT mustafamona theaddedvalueofpsmapetmrradiomicsforprostatecancerstaging
AT weberwolfgang theaddedvalueofpsmapetmrradiomicsforprostatecancerstaging
AT navabnassir theaddedvalueofpsmapetmrradiomicsforprostatecancerstaging
AT eibermatthias theaddedvalueofpsmapetmrradiomicsforprostatecancerstaging
AT hattmathieu theaddedvalueofpsmapetmrradiomicsforprostatecancerstaging
AT nekollastephang theaddedvalueofpsmapetmrradiomicsforprostatecancerstaging
AT solariestebanlucas addedvalueofpsmapetmrradiomicsforprostatecancerstaging
AT gafitaandrei addedvalueofpsmapetmrradiomicsforprostatecancerstaging
AT schachoffsylvia addedvalueofpsmapetmrradiomicsforprostatecancerstaging
AT bogdanovicborjana addedvalueofpsmapetmrradiomicsforprostatecancerstaging
AT villagranasiaresalberto addedvalueofpsmapetmrradiomicsforprostatecancerstaging
AT amielthomas addedvalueofpsmapetmrradiomicsforprostatecancerstaging
AT huiwang addedvalueofpsmapetmrradiomicsforprostatecancerstaging
AT rauscherisabel addedvalueofpsmapetmrradiomicsforprostatecancerstaging
AT visvikisdimitris addedvalueofpsmapetmrradiomicsforprostatecancerstaging
AT maurertobias addedvalueofpsmapetmrradiomicsforprostatecancerstaging
AT schwambornkristina addedvalueofpsmapetmrradiomicsforprostatecancerstaging
AT mustafamona addedvalueofpsmapetmrradiomicsforprostatecancerstaging
AT weberwolfgang addedvalueofpsmapetmrradiomicsforprostatecancerstaging
AT navabnassir addedvalueofpsmapetmrradiomicsforprostatecancerstaging
AT eibermatthias addedvalueofpsmapetmrradiomicsforprostatecancerstaging
AT hattmathieu addedvalueofpsmapetmrradiomicsforprostatecancerstaging
AT nekollastephang addedvalueofpsmapetmrradiomicsforprostatecancerstaging